# Open Orphan clinical laboratories awarded high standard of excellence by CAP

- Link: https://www.directorstalkinterviews.com/open-orphan-clinical-laboratories-awarded-high-standard-of-excellence-by-cap/4121080213
- Published: 2022-09-01T07:37:52+01:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist contract research organisation (CRO) and world leader
in testing infectious and respiratory disease products using human challenge clinical
trials, has announced that its clinical laboratories in Queen Mary’s Bioenterprise
Centre and Plumbers Row (hLab) have been awarded accreditation by the College of
American Pathologists (“CAP”). The Company sought the accreditation as part of its
ongoing commitment to maintaining best in class quality systems.

The CAP is the world’s largest organisation of board-certified pathologists and 
leading provider of laboratory accreditation and proficiency testing programmes.
The accreditation “supports laboratories performing testing on specimens from human,
using methodologies and clinical application within the expertise of the program”.
This further expands on the Company’s Good Clinical Practice for Laboratories (GCLP)
accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA)
and provides additional quality assurances of its laboratory services for its clients,
especially within the United States, thus ensuring the accuracy of test results 
and conforming to the requirements from the US Food and Drug Administration (FDA).

[hLab](https://hvivo.com/laboratory-services/) is a highly specialised virology 
and immunology laboratory, offering a suite of services to support both pre-clinical
and clinical respiratory drug and vaccine discovery and development. This includes
assay development, transfer and optimisation across immunology, molecular and cell-
based assays, including extensive options in sample matrix and stability testing
and analysis. hLab is well equipped with Biosafety Level 2 and 3 facilities to provide
high quality data outputs to enable clients to achieve early proof of concept, or
to make a breakthrough discovery in the pathology and possible treatment of diseases
with unmet medical needs. hLAB now provides services beyond supporting the Company’s
in-house human challenge trials, offering lab services as a standalone service to
support vaccine and drug development from pre-clinical studies through Phases I –
III clinical trials.

> **Brandon Londt, Development Operations Director, hLab Development at** **hVIVO,
> said:** _“We are proud to have received the CAP accreditation, which is recognition
> of the quality of our laboratory and further demonstrates our commitment to maintaining
> the highest standards of excellence and ensuring that our work practices meet 
> the rigorous CAP assessment standards. This accreditation will provide current
> and future clients a further degree of confidence in the quality of work performed
> in our laboratory and assurances of the results we produce.”_

Share on: